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I. Introduction
2007 saw numerous health law issues impact the international community and garner
world-wide attention. Some of these issues involved business and financial concerns re-
lated to international health law (e.g., patents, trade, business development, and pharma-
ceutical pricing); others pertained to the myriad ways in which the health of individuals
and communities around the world can be impacted by health-related laws and regula-
tions. The events of 2007 seem to highlight, once again, that globalization is occurring
more quickly than the law on pertinent topics is emerging. As this trend continues, the
international health law community will be challenged to keep pace, to establish and
maintain relevant rule of law initiatives, and to become more proactive in establishing
broad-based and widely-accepted, enforceable standards that the global community can
agree upon and that will positively impact the health of individuals and communities.
II. Trade and Intellectual Property Law
A. PATENT LAWS
Efforts to conform U.S. patent laws to international standards continued in 2007, with
discussions between the United States and other "Group B-Plus" countries.' Although
these discussions were ostensibly intended to result in an international patent harmoniza-
tion treaty, accord has yet to be reached on several critical issues. In particular, the Euro-
pean Union and others have insisted on uniform recognition of a "first to file" patent
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1. "Group B-Plus" countries are members of the World Intellectual Property Organization (XVIPO) and
include Australia, Canada, the European Patent Convention Member States, the European Union Member
States, Japan, New Zealand, Norway, and the United States. See Comments Sought on Harmonization of U.S.
Patent Laws with Those of Other Countries, 74 PAT.,TRADEAMARK & COPYRIGHT J. (BNA) 67, 67-68 (2007).
746 THE INTERNATIONAL LAWYER
standard, 2 which is not consistent with the "first to invent" standard under current U.S.
law. A "grace period" has been offered as a potential solution, permitting patent protec-
tion if information relevant to the patent application has entered the public domain. But
the United States and other countries have not reached agreement on the scope of such a
grace period, with the United States requesting an eighteen-month grace period and other
countries seeking a limited application of the grace period. 3 Further discussions between
the Group B-Plus countries have been proposed,4 but legislation pending in both houses
of the U.S. Congress would change the U.S. priority standard to the generally favored
first to file, presumably rendering negotiations over the scope of a grace period moot.
5
In addition to harmonization, patent law regimes in developing countries remain a fer-
tile ground for legal challenges by multinational drug manufacturers. For example, recent
changes to Indian patent law demonstrate controversies arising from jurisdiction-specific
patentability standards. In May 2006, Novartis AG filed an action challenging the Indian
patent office's rejection of a patent application covering the Novartis oncology drug
Gleevec. The Indian patent office based its rejection on section 3(d) of the Indian patent
statute, which precludes patenting modifications or new uses of an existing drug unless
such modifications or new uses significantly increase the drug's effectiveness. 6 Novartis
argued that section 3(d) was in violation of the Indian Constitution and the World Trade
Organization's (WTO) Agreement on Trade-Related Aspects of Intellectual Property
Rights (TRIPS). On August 6, 2007, the Madras High Court in Chennai rejected the
constitutional challenge but deferred conclusion as to TRIPS compliance to the WTO.
7
Novartis has also filed a separate appeal with the Indian Intellectual Property Appellate
Board concerning the patentability of Gleevec under Indian patent law.8
B. WORLD TRADE ORGANIZATION
In December 2005, WTO members adopted a public health amendment to TRIPS,
instituting an August 2003 WTO agreement allowing greater utilization of compulsory
licenses to export generic pharmaceuticals to countries lacking production capabilities suf-
ficient to produce the pharmaceuticals in-country.9 While the proposed TRIPS amend-
2. Under the "first to file" standard, patent protection arises only from the date of patent filing. By
contrast, under the "first to invent" standard under current United States law, patent protection is granted
from the time an invention is made.
3. One limited application could arise in the context of academic research, where publication demands
may require public disclosure of patentable subject matter prior to the filing of a patent application.
4. See Daniel Pruzin, Unresolved Issues Stall Developed Country Talks on Global Patent Treaty, 74 PAT.,
TRADEMARK & COPYRIGHT J. (BNA) 410 (2007).
5. H.R. 1908 and S. 1145 were approved respectively by the House and Senate Judiciary Committees in
July 2007. See, e.g., Anandashankar Mazumdai & Yousef Siddiqui, Senate Judiciary Accepts Amendments to
Patent Reform Bill, More Markup Expected, 74 PAT.,TRADEMARK & COPYRIGHT J. (BNA) 341 (2007); Senate
Judiciary Committee Approves Patent Refiorm Bill in Evening Session, 74 PAT.,TRADEMARK & COPYRIGHT J.
(BNA) 370 (2007).
6. See The Patents (Amendment) Act, 2005, No. 15, Acts of Parliament, 2005, available at http://india
code.nic.in/fullact I.asp?tfnm=200515.
7. Novartis, Advocacy Group React to Indian Court's Rection of Patent Law Challenge, 74 PAT., TRADEMARK
& COPYRIGHT J. (BNA) 455 (2007).
8. Id.
9. See, e.g., William New, N~ews Mixed on W7O Doba Declaration on Public Health After Five Years, INTEL-
LECTUAL PROPERTY WATCH, Nov. 16, 2006, available at http://www.ip-watch.org/webog/index.php?p=460.
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ment was formally accepted by WATO members in December 2005, it will not become
effective until ratified by two-thirds of the WTO's 151 members. December 1, 2007, was
initially established as the date by which the WITO expected to have the necessary ratifica-
tions. By that date, however, only eleven members had ratified the amendments, with the
European Parliament recently ratifying the amendment and opening the door to ratifica-
tion by European Union Member States.10 Due to the extended length of time this pro-
cess is taking, VTO members agreed in October 2007 to delay the ratification deadline
until December 1, 2009.11
Although this amendment has not yet taken effect, a number of countries argue that
such compulsory licensing is already permissible under TRIPS. For example, in late 2006,
Thailand announced that it would use compulsory licensing as permitted under TRIPS
for antiviral AIDS drugs efavirenz12 and lopinavir/ritonavir]3 and for the cardiac therapy
drug clopidogrel.' 4 But Thailand's Health Minister Mongkol na Songkhla stated on May
15, 2007, that Thailand would not enforce such compulsory licenses if the companies
responsible for these drugs "agree to reduce the price of their drugs below generic
ones."15 On May 4, 2007, after failing to reach a negotiated agreement with Merck,16
Brazil issued a compulsory license for efavirenz, stating that it would import the drug from
India and pay a royalty to Merck of 1.5 percent. 17 Finally, on July 19, Rwanda notified
the WTO of its intention to import 260,000 packages of the antiviral cocktail Apo-
triAvir' 8 pursuant to TRIPS.19
10. See, e.g., International Centre for Trade and Sustainable Development, European Parliament Ratifies
TRIPS Amendment, 11 BRIDGES WEEKLY TRADE NEWS DIGEST 36, Oct. 24, 2007, available at http://
www.ictsd.org/weekly/07-10-24/story2.htm. If each European Union Member State ratifies the amendment,
the number of ratifying WTO members will rise to thirty-eight. Id.
11. See id.
12. Marketed by Merck & Co. under the brand name Stocrin.
13. Marketed by Abbott Laboratories under the brand name Kaletra.
14. Marketed by Bristol-Myers Squibb under the brand name Plavix.
15. PhRMA Chief Says Thai Officials Indicate They Still Want Negotiations on Drug Prices, 74 PAT., TRADE-
MARK & COPYRIGIHI J. (BNA) 156 (2007) (May 15, 2007 statement made during conference call from Ge-
neva, Switzerland).
16. Brazil offered to purchase efavirenz from Merck at $0.65 per pill, a price equivalent to the price paid to
Merck by Thailand for efavirenz. Merck countered with an offer to reduce the per pill cost by 30 percent to
$1.10. See Ed Taylor, Brazil Breaks Patent on Merck AIDS Drug, 74 PAT., TRADEMARK & COPYRIGHT J.
(BNA) 65, at 65-66 (2007).
17. Id.
18. Apo-triAvir, manufactured by Apotex, Inc., is a combination therapy consisting of Zidovudine,
Lamivudine, and Nevirapine.
19. See Rwanda Notifies WTO of Plans to Import Medicines Under New TRIPS Rides, 74 PAT., TRADEMARK &
COPYRIGHTJ. (BNA) 412 (2007). It is noteworthy that neither Brazil nor Thailand is required to apply the
proposed TRIPS amendment to issue compulsory licenses for efavirenz, as each intended to import generic
copies from India where the drug is not patented. But Rwanda has proposed to import Apo-triAvir from
Canada under WTO procedures identical to the proposed amendment. See International Centre for Trade
and Sustainable Development, Canadian 14TO Notification Clears Path for Rwanda to Import Generic HIV/AIDS
Drug, 11 BRIDGES WEEKLY TRADE NEWS DIGEST 34, Oct. 10, 2007, available at http://www.ictsd.org/
weekly/07-10-10/story4.htm.
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C. WORLD HEALTH ORGANIZATION
In 2007, the World Health Organization (VHO) continued to emphasize its strong
interest in the application of TRIPS in service of its mission to promote increased access
to pharmaceuticals and its intention to provide guidance and assistance regarding TRIPS-
related matters. At the close of the World Health Assembly on May 23, 2007, the Assem-
bly reached agreement on a resolution requesting that the WHO Director-General con-
tinue to support the work of the Intergovernmental Working Group on Public Health,
Innovation and Intellectual Property (1WG) and guide the IWG in the creation of a strat-
egy and plan of action. 20 Additionally, the May 23 WHO resolution directed the Direc-
tor-General "to provide as appropriate, upon request, in collaboration with other
competent international organizations, technical and policy support to countries that in-
tend to make use of the flexibilities" authorized under TRIPS.21 On July 31, 2007, the
IWG issued its draft strategy and plan of action to promote "needs-driven, essential re-
search and development relevant to diseases that disproportionately affect developing
countries. ' ' 22 To be implemented in full by 2015, the proposed global strategy acknowl-
edges the vital importance of intellectual property in research and development but
stresses that "alternative and/or additional incentive schemes for research and develop-
ment" into certain diseases should be explored and implemented. 23
The WHO also continues to expand its international clinical trial registry in order to
promote transparency with regard to clinical research and the dissemination of informa-
tion concerning diseases and potential treatments. On July 25, 2007, the WHO an-
nounced that registers from China and India would be included in the WHO registry.24
It should be noted that response to the WHO's initiatives concerning public health,
intellectual property, and innovation has not been uniformly positive. The United States
did not endorse the May 23, 2007, World Health Assembly resolution, and international
pharmaceutical companies have been outspoken in their disagreement with the WHO's
strategy pertaining to intellectual property matters.25
D. UNITED STATES TRADE REPRESENTATIVE
The United States Trade Representative (USTR) has continued to promote protection
and enforcement of intellectual property rights (IPR) and innovation, creating in June
2006 a new Office of Intellectual Property and Innovation and appointing a Chief Negoti-
20. Press Release, World Health Organization, World Health Assembly Closes: Agreement Reached on
Influenza Virus Sharing, Intellectual Property (May 23, 2007), available at http://www.who.int.mediacentre/
newslreleases/2007/wha02/en/index.html [hereinafter WHA Closes].
21. Daniel Pruzin, WHO Urged to Aid Governments in Implementing TRIPS/Medicines Deal, 74 PAr.,
TRADEMARK & COPYRIGHT J. (BNA) 157 (2007); see also WrHA Closes, supra note 20.
22. WHO, Intergovernmental Working Group on Public Health, Innovation and Intellectual Property,
Report by the Secretariat: Draft Global Strategy and Plan of Action on Public Health, Innovation and Intellectual
Property, A/PHI/IGWG/2/2 (Jul. 3, 2007), at 3, available at http://www.who.int/gb/phi/E/indexE.html.
23. Id. at 8.
24. See Press Release, World Health Organization, China and India Join WHO Clinical Trial Registry
Platform (Jul. 25, 2007), available at http://www.who.int/mediacentre/news/releases/2007/pr4l/en/index.
html.
25. See, e.g., Daniel Pruzin, Drug Indettry Slams WHO Draft Global Strategy for Public Health Rights, IP
Rights, 75 PAT., TRADEMARK & COPYRIGHT J. (BNA) 42, 42-43 (2007).
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ator for Intellectual Property Enforcement. In its annual Special 301 Report,26 the USTR
again highlighted its concerns with respect to IPR protection by China and Russia. The
USTR indicated that while the United States and Russia entered into a bilateral market
access agreement in November 2006, Russia would nonetheless be subject to an "Out-of-
Cycle Review" 27 to evaluate progress in IPR protection; additionally, the USTR has filed
requests for WTO dispute settlement consultations with China to address deficiencies in
China's legal protection and enforcement of trademarks and copyrights on a wide range of
products, as well as China's barriers to trade in books, videos, and music. 28 Specifically,
the USTR has alleged violations of TRIPS related to three aspects of China's IPR regime:
(1) "quantitative thresholds in China's criminal law" to initiate prosecution for copyright
piracy and trademark counterfeiting; (2) "rules for disposal of IPR-infringing goods seized
by Chinese customs authorities"; and (3) "denial of copyright protection for works poised
to enter the market but awaiting Chinese censorship approval." 29
The USTR 2007 Special 301 Report articulates the following concern with the global
trade in counterfeit pharmaceuticals:
The manufacture and distribution of counterfeit pharmaceuticals is a growing prob-
lem that poses special concerns for consumer health and safety. The United States
notes its concern with the proliferation of the manufacture of counterfeit
pharmaceuticals in China, India, and Russia, and the sale and distribution of counter-
feit pharmaceuticals in many countries. A significant contributing factor in this prob-
lem is the unauthorized use of bulk active pharmaceutical ingredients (APIs) to
manufacture counterfeit pharmaceuticals. Countries must do more to provide its [sic]
relevant agencies with the authority to regulate and enforce against the unauthorized
use of APIs domestically and to ensure that they are not exported for unauthorized
use abroad. Also, countries must do more to enforce vigilantly against the manufac-
ture and distribution of counterfeit pharmaceuticals. 30
26. OFFICE OF THE U.S. TRADE REPRESENTATIVE, SPECIAL 301 REPORT 5 (2007), available at http://
www.ustr.gov/assets/Document_- Library/ReportsPublications/2007/2007_Special_301_Review/asset -upload
.file230_l 1122.pdf [hereinafter SPECIL 301 REPORT]. "The 'Special 301' Report is an annual review of the
global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the
United States Trade Representative (USTR) pursuant to Special 301 provisions of the Trade Act of 1974." Id.
at 2.
27. An "Out-of-Cycle Review" is a review by the USTR of a country's IPR policies and practices generally
undertaken outside the standard annual review. Other countries to be subject to an Out-of-Cycle Review in
2007-2008 include Brazil, the Czech Republic, and Pakistan. See id. at 8, 30, 34.
28. See id. at 15-16.
29. Press Release, Office of the United States Trade Representative, United States Requests WTO Panel in
Case Challenging Deficiencies in China's Intellectual Property Rights Laws (Aug. 13, 2007), available at
http://www.ustr.gov/Document -Library/PressReeases/2007/August/United-States-Requests-WTO-
Panel in-Case ChallengingDeficiencies-inChina'sIntellectualPropertyRightsLaws.html.
30. SPECIAL 301 REPORT, supra note 26, at 6. The WHO estimates that counterfeit pharmaceuticals com-
prise approximately 1% of sales in developed countries, more than 10% in developing countries, more than
20% in former Soviet republics, and approximately 30% in parts of Africa, Asia, and Latin America. See Press
Release, World Health Organization, WHO-Led Anti-Counterfeiting Coalition Examines Technology to
Prevent Fake Drugs (Mar. 13, 2007), available at http://www.who.int/mediacentre/news/releases/2007/pr7/
en/index.hunl.
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While this statement addresses the potential public health risks arising from counterfeit
pharmaceuticals, the 2007 Special 301 Report also provides farther documentation of con-
tinued USTR preference for strong intellectual property protection and the apparent ten-
sion between policies of innovation and public health. For example, while the 2007
Special 301 Report does not directly condemn Thailand's use of compulsory licensing
under TRIPS, acknowledging a "country's ability to issue such licenses in accordance with
WTO rules," it raises concerns with "the lack of transparency and due process" involved
in Thailand's decision.31 Similarly, while the 2007 Special 301 Report downgraded Brazil
from the USTR's "Priority Watch List" to the "Watch List," the USTR urges that Brazil
engage "in open and transparent discussions with all relevant stakeholders" when it con-
siders utilization of compulsory licenses, and it also noted that Brazil would be subject to
an Out-of-Cycle Review, suggesting that utilization of compulsory licenses may be the
focus of increased USTR scrutiny in the future.
32
While the USTR acknowledges rights provided to countries under TRIPS, a 2007 U.S.
Government Accountability Office (GAO) report, drafted at the request of members of
the U.S. Congress, provides an analysis of what is sometimes viewed as the USTR's over-
emphasis on intellectual property protections at the expense of public health benefits aris-
ing from early and enhanced access to generic drugs.33 Ultimately, the GAO report
recommended congressional clarification of U.S. trade policy and public health policy in
order to eliminate potential disparities between USTR practice and congressional
intent.34
III. Transparency in Pharmaceutical Pricing
A. REGULATING THE REIMBURSEMENT AND PRICING OF MEDICINES
Governments continue to experiment with procedures for making decisions about the
appropriate use of medicines in public health programs, including procedures that deter-
mine which medicines will be reimbursed, at what price, and for which patients. 35 In
2007, several countries moved to revisit and modify reimbursement and pricing schemes
in an attempt to control drug prices. In February 2007, the United Kingdom's Office of
Fair Trading (OFT) recommended a complete overhaul of the price and profit controls
system utilized under the Pharmaceutical Pricing Regulation Scheme (PPRS), advising
that the system be replaced with a value-based approach to pricing in order to more effec-
tively utilize government funds allocated for healthcare services, as well as to provide drug
31. Id. at 27.
32. Id. at 30.
33. U.S. GOV'T ACCOUNTABILITY OFFICE, U.S. TRADE POLICY GUIDANCE ON WTO DECLARATION ON
ACCESS TO MEDICINES MAY NEED CLARIFICATION (Sept. 2007), available at http://www.gao.gov/new.items/
d071198.pdf.
34. Id. at 58.
35. See e.g., Alan Maynard & Karen Bloor, Dilemmas in the Regulation of the Market for Pharmaceuticals, 22
HEALTH AFF. 31 (2003), available at http://content.healthaffairs.org/cgi/reprint/22/3/31 .pdf; AARP PUBLIC
POLICY INST., EUROPEAN EXPERIENCES WITH PRESCRIPTION DRUG PRICING (Oct. 2006), available at
http://assets.aarp.org/www.aarp.org_/cs/gap/ldrstudy-prescdrugs.pdf.
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companies with better incentives to invest in drugs that would benefit patients. 36 Japan's
Ministry of Health, Labor, and Welfare followed with an announcement in May 2007 that
the Ministry is considering policies to double the use of generic drugs by 2012. 37 And
U.S. lawmakers proposed bills to improve consumer access to generic biologic drugs38 , as
well as to allow the Department of Health and Human Services to negotiate Medicare
Part D prices.39
Increased attention has been focused on the transparency of government reimburse-
ment and pricing processes as well as on the opportunity for meaningful participation in
the system by interested stakeholders, such as patients and drug companies. This year, for
the first time, a drug manufacturer, Eisai Limited (Eisai),40 filed a case in the United
Kingdom High Court, challenging a decision by the National Institute for Health and
Clinical Excellence (NICE) - a health authority within the National Health Service
(NHS) that develops drug coverage guidance for the NHS - not to reimburse Alzheimer's
drugs for patients with less severe forms of the disease.41 Eisai argued that the process by
which the decision was reached was procedurally unfair, irrational, and discriminated
against certain patient groups. The High Court ruled that while the petitioner did not
demonstrate that the decision was procedurally unfair or irrational, NICE's failure to pro-
vide sufficient guidance with respect to the treatment of atypical patient groups was dis-
criminatory. 42 The High Court ruling does not require NICE to reconsider its initial
coverage decision, and Eisai has filed an appeal to the Court of Appeal based on NICE's
refusal to disclose the full record on which they based their decision.
The USTR also continued its focus on increased transparency in reimbursement and
pricing decisions. In June 2007, the USTR finalized a bilateral free trade agreement
(FTA) with South Korea that included provisions aimed at providing additional trans-
parency and meaningful participation rights for interested stakeholders in the South Ko-
rean drug pricing and reimbursement process. 43 As part of South Korea's obligations, the
government has committed to establishing an independent body - separate from the
health authority responsible for making coverage and pricing decisions - to review cover-
age and pricing decisions for drugs and devices upon a company's request. 44 The U.S.-
South Korea FTA builds upon the obligations set forth in the 2005 U.S.-Australia FTA45
36. OFFICE OF FAIR TRADING, THE PHARMACEUT'rCAL PRICE REGULATION SCHEME: AN OFT MARKET
STUDY 5 (Feb. 2007), available at http://www.oft.gov.uk/sharedoft/reports/comp-policy/oft885.pdf.
37. Tomoki Matsubara & Yasushi Kouchi, The Brave New World of Generic Drugs, DAILY YOMIURI (Tokyo),
Jul. 11, 2007, at 4.
38. Biologics Price Competition and Innovation Act of 2007, S. 1695, 110th Cong. (2007).
39. Medicare Prescription Drug Price Negotiation Act of 2007, S. 3, 110th Cong. (2007).
40. Pfizer and the Alzheimer's Society participated in the case as interested parties.
41. See Eisai Ltd. v. Nat'l Inst. for Health & Clinical Excellence, [2007] EWHC (Admin) 1941 (England).
42. See id. at [60]-[611, [961, [116], [1221.
43. Free Trade Agreement Between the United States and the Republic of Korea, U.S.-Korea, art. 5.3,
June 30, 2007, available at http://www.ustr.govTradeAgreements/Bilateral/Republic-ofKorea-FTA/Final-
Text/SectionIndex.html [hereinafter U.S.-Korea FTA].
44. Confirmation Letter (Indep. Review Body) from Hyun Chong Kim, S. Korean Minister of Trade, to
Hon. Susan Schwab, U.S. Ambassador (June 30, 2007), available at http://www.ustr.gov/assets/Trade-Agree-
ments/Bilateral/Republic-ofKoreaFTA/Final Text/assetupload-file511 12725.pdf.
45. U.S.-Australia Free Trade Agreement, U.S.-Austl., Annex 2-C, art. 2 (May 18, 2004), available at
http://www.ustr.govfTrade-Agreements/Bilateral/Australia TA/FinalText/Section-Index.html [hereinafter
U.S.-Australia FTA]. The transparency provisions of the U.S.-Australia FTA include requirements for timely
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but includes more detailed obligations with respect to rights of participation and transpar-
ent processes.46
IV. Individual and Community Rights Related to Public Health Law
A. THE EXAMPLE OF DRUG-RESISTANT TUBERCULOSIS
The widely-publicized case of Andrew Speaker, a patient with drug-resistant tuberculo-
sis who traveled through a number of countries, including the United States, Greece,
Italy, and Canada, served to underscore the lack of a clear, comprehensive, and standard-
ized approach to sharing information and taking appropriate action quickly and efficiently
in response to communicable diseases that may threaten the health of the international
community. 47
In the United States, this situation led to concerns about vulnerability to bioterrorism
and subsequent congressional hearings reaffirmed the need to examine and update the
system for addressing such issues. 48 Additionally, the incident raised concerns in the in-
ternational community, and although the VHO added its voice to those criticizing the
manner in which the United States handled the case, this incident also calls attention to
the need for oversight and enforcement as individual countries attempt to establish a co-
herent system of health care laws and regulations consistent with the newly-revised Inter-
national Health Regulations promulgated by the WHO.4 9
While the law has historically recognized that individual rights may be circumscribed
for the public health benefit of the community (e.g., mandatory vaccinations, quarantine),
there has almost always been some debate about where and how to draw the line between
individual rights, the public health rights of the community, and the government's right to
enforce public health laws and regulations.50 Furthermore, there has traditionally been a
significant debate regarding whether laws and regulations are an effective means to ad-
dress communicable diseases or whether such laws make the situation worse by driving
people underground, away from screening and treatment resources.
Another recent case that drew attention to these concerns and also raised the issue of
whether current laws and regulations effectively address international travel and commu-
nicable diseases is that of Robert Daniels, who was born and diagnosed with tuberculosis
decision-making, an opportunity for comment at key stages in the decision-making process, publication of
procedural rules, access to detailed information on the basis for the decision, written information to the
public concerning decision, and establishment of an independent review mechanism.
46. Compare U.S.-Korea FTA, supra note 43, art. 5.3, with U.S.-Australia FTA, supra note 45, Annex 2-C,
art. 2.
47. See Denise Grady, TB Patient Says Officials are Trying to Blame Him to Cover Mistakes, N.Y. TNIMES, June
9, 2007, available at http://www.nytimes.com/2007/06/09/us/09tb.html.
48. See Lawrence K. Altman & Jaqueline Palank, TB Patient Gives His Account to Congress, N.Y. TIMES, June
7, 2007, available at http://www.nytimes.com/2007/06/07/us/O7tb.html.
49. See David Brown, WHO Faults Handling of TB Case, WASH. Posr, June 6, 2007, at A3, available at
http://www.washingtonpost.com/wp-dyn/content/artice/2007/06/05/AR2007060502438.html; see WrHO,
International Health Regulations (2005), http://www.who.int/csr/ihr/en/ (last visited Feb. 11, 2008).
50. See, e.g., John D. Blum & Norchaya Talib, Balancing Individual Rights Verms Collective Good in Public
Health Enforcement, 25 MED. & L. 273 (2006); Robyn Martin, Commentary, The Erercise of Public Health
Powers in Cases of Infectious Disease: Human Rights Implications, 14 MED. L. REv. 132 (2006).
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in Russia, then later, while still sick, flew to the United States.5 In the United States,
Daniels was diagnosed with drug-resistant tuberculosis, and after failing to comply with
his treatment regimen, he was confined by court order to the jail unit of an Arizona hospi-
tal.5 2 Daniels received medical treatment while in the jail unit, but he was also treated like
an inmate (e.g., he could not leave, was subject to strip searches, and was not permitted to
go outside the facility), and the situation became a case study for examining the wisdom of
using the criminal justice system to address public health issues. 53 Due to concerns about
violations of Daniels' civil rights, the American Civil Liberties Union (ACLU) sued on his
behalf, arguing that his confinement was unconstitutional.54 Following the filing of the
ACLU lawsuit and almost a year after his confinement started, Daniels was transferred out
of the jail unit and to a Colorado hospital for treatment. 55
B. TRADE AND PUBLIC HEALTH
In addition to people traveling internationally, the global marketplace has resulted in
increasing numbers of goods traveling internationally. A number of newsworthy stories in
2007 focused on the role of international trade, inconsistent health regulations, and inef-
fective enforcement mechanisms pertaining to international exposure to contaminants.
Toothpaste from China mixed with diethylene glycol, an antifreeze ingredient, was
found in Panama, Costa Rica, Australia, the Dominican Republic, and the United States. 56
A similar situation occurred in Panama involving the same ingredient from China mixed
into cold medicine and resulted in the deaths of at least 100 people.57 Additionally, toys
manufactured in China have been found to contain unacceptable levels of lead paint, pet
food from China has been found to contain a contaminant thought to have contributed to
a number of animal deaths, and various food products from China have been reported as
being of questionable safety.58
China has clearly taken this situation seriously. Following the publicity surrounding a
number of these situations, China signed an agreement prohibiting lead paint in toys ex-
51. See Richard Knox, Arizona TB Patient jailed as a Public Health Menace (NPR radio broadcast June 11,
2007), available at http://www.npr.org/templates/story/story.php?storyld=10874970.
52. See id.
53. See Press Release, American Civil Liberties Union, ACLU of Arizona Lawsuit Triggers Transfer of TB
Patient to Denver Hospital (Jul. 17, 2007), available at http://www.aclu.org/prison/gen/30618prs200707
17.html [hereinafter ACLU Lawsuit Triggers].
54. See Press Release, American Civil Liberties Union, ACLU of Arizona Sues County Officials Over In-
humane Confinement of TB Patient (May 31, 2007), available at http://www.aclu.org/privacy/gen/29941prs
20070531 .htnl.
55. See ACLU Lawsuit Triggers, supra note 53.
56. See Walt Bogdanich & Renwick McLean, Poisoned Toothpaste in Panama is Believed to be From China,
N.Y. TIMES, May 19, 2007, available at http://www.nytimes.comI/2007/05/19/world/americas/19panama.
html; Reuters, Costa Rica Seizes Contaminated Toothpaste Imported From China, N.Y. TIMES, May 26, 2007,
available at http://www.nytimes.com/2007/05/26/world/americas/26toothpaste.html; Walt Bogdanich, Toxic
Toothpaste Made in China is Found in U.S., N.Y. TIMES, June 2, 2007, available at http://www.nytimes.com/
2007/06/02/us/02toothpaste.html.
57. See Bogdanich & McLean, supra note 56.
58. Louise Story, Lead Paint Prompts Mattel to Recall 967,000 Toys, N.Y. TIMES, Aug. 2, 2007, available at
http://www.nytimes.com/2007/08/02/business/02toy.html; Nicholas Zamiska, Who's Monitoring Chinese Food
Exports?, WALL ST. J., Apr. 13, 2007, available at http://yaleglobal.yale.edu/display.artice?id=9053.
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ported to the United States.59 Also, to the dismay of some human rights groups, China
executed the former head of the State Food and Drug Administration in July 2007, osten-
sibly because he took bribes to approve medicines-although there has been speculation
that the harsh sentence was more likely attributable to recent bad press and trade
concerns.
60
Moreover, while recent news stories may have focused on China, it is not clear that
these product safety and quality control issues are limited to China. The more important
message seems to be that as our world becomes an increasingly global community,
stronger, more consistent regulations are needed in order to establish safe international
trade that provides equal protection for all people.
V. Conclusion
As the world becomes a more integrated, mobile, and shared community, the interna-
tional health, legal, and business sectors will have to adopt innovative new strategies if
they hope to successfully address the needs of this emerging global community. Consis-
tent with history, the rights of all people, including vulnerable populations, are key to
international health and security. The WHO, the WTO, and numerous countries, busi-
nesses, organizations, and individuals have provided and continue to provide progressive
international health law leadership to the global community; all of these entities, however,
must do more to establish a cohesive, coherent, secure framework that promotes, sup-
ports, and protects the health of all.
59. See Associated Press, China Signs Pact to Ban Lead Paint in Export Toys, N.Y. TIMEs, Sept. 12, 2007,
available at http://www.nytimes.com/2007/09/12/business/worldbusiness/12lead.html.
60. See Joseph Kahn, China Quick to Erecute Drug Official, N.Y. TIMES, Jul. 11, 2007, available at http://
www.nytimes.com/2007/07/1 1/business/worldbusiness/1 lexecute.html.
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